Whitepaper | 12/1/2020

Transforming the Regulatory Landscape for Digital Health Technologies in Drug Development

Julia A. Gaebler, PhD, Chelsea Pan, PhD, and John Latimer, in collaboration with Biogen Inc.
As tools that harness data to develop solutions for health applications, digital health technologies (DHTs) hold tremendous promise to transform the lives of patients and the management of diseases. This paper summarizes the value of DHTs in drug development and highlights the inherent challenges of the current regulatory paradigm in the US and Europe.
Read here.

Share this: